Shilpa Medicare
Market Cap
₹38.2b
Last Updated
2020/10/25 13:01 UTC
Data Sources
Company Financials +
Executive Summary
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (API’s), intermediates, and formulations in India, the United States, Europe, and internationally.. More Details
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Shilpa Medicare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 530549's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.1%
530549
-0.8%
IN Pharmaceuticals
1.4%
IN Market
1 Year Return
74.0%
530549
48.4%
IN Pharmaceuticals
2.8%
IN Market
Return vs Industry: 530549 exceeded the Indian Pharmaceuticals industry which returned 48.4% over the past year.
Return vs Market: 530549 exceeded the Indian Market which returned 2.8% over the past year.
Shareholder returns
| 530549 | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.1% | -0.8% | 1.4% |
| 30 Day | -17.2% | 3.0% | 8.0% |
| 90 Day | -6.0% | 12.3% | 7.8% |
| 1 Year | 74.5%74.0% | 50.2%48.4% | 4.5%2.8% |
| 3 Year | -28.2%-28.8% | 25.7%22.3% | -0.5%-5.3% |
| 5 Year | 0.5%-0.6% | 0.5%-3.1% | 41.5%31.0% |
Price Volatility Vs. Market
How volatile is Shilpa Medicare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall St
Will Shilpa Medicare Limited (BOM:530549) Continue To Underperform Its Industry?2 years ago | Simply Wall St
Top BSE Growth Stocks To Buy2 years ago | Simply Wall St
Top BSE High Growth StockValuation
Is Shilpa Medicare undervalued compared to its fair value and its price relative to the market?
16.83x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 530549 (₹468) is trading above our estimate of fair value (₹163.27)
Significantly Below Fair Value: 530549 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 530549 is good value based on its PE Ratio (16.8x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: 530549 is poor value based on its PE Ratio (16.8x) compared to the Indian market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: 530549 is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: 530549 is overvalued based on its PB Ratio (2.9x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is Shilpa Medicare forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
5.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 530549's forecast earnings growth (5.1% per year) is below the savings rate (7.2%).
Earnings vs Market: 530549's earnings (5.1% per year) are forecast to grow slower than the Indian market (25.9% per year).
High Growth Earnings: 530549's earnings are forecast to grow, but not significantly.
Revenue vs Market: 530549's revenue (11.3% per year) is forecast to grow slower than the Indian market (11.4% per year).
High Growth Revenue: 530549's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 530549's Return on Equity is forecast to be low in 3 years time (13.2%).
Next Steps
Past Performance
How has Shilpa Medicare performed over the past 5 years?
12.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530549 has a large one-off gain of ₹762.7M impacting its June 30 2020 financial results.
Growing Profit Margin: 530549's current net profit margins (23.4%) are higher than last year (13.5%).
Past Earnings Growth Analysis
Earnings Trend: 530549's earnings have grown by 12.1% per year over the past 5 years.
Accelerating Growth: 530549's earnings growth over the past year (140%) exceeds its 5-year average (12.1% per year).
Earnings vs Industry: 530549 earnings growth over the past year (140%) exceeded the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: 530549's Return on Equity (17.1%) is considered low.
Next Steps
Financial Health
How is Shilpa Medicare's financial position?
Financial Position Analysis
Short Term Liabilities: 530549's short term assets (₹6.2B) exceed its short term liabilities (₹4.1B).
Long Term Liabilities: 530549's short term assets (₹6.2B) exceed its long term liabilities (₹2.6B).
Debt to Equity History and Analysis
Debt Level: 530549's debt to equity ratio (24.8%) is considered satisfactory.
Reducing Debt: 530549's debt to equity ratio has reduced from 28.7% to 24.8% over the past 5 years.
Debt Coverage: 530549's debt is well covered by operating cash flow (37.7%).
Interest Coverage: 530549's interest payments on its debt are well covered by EBIT (29.8x coverage).
Balance Sheet
Next Steps
Dividend
What is Shilpa Medicare current dividend yield, its reliability and sustainability?
0.24%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 530549's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: 530549's dividend (0.24%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).
Stability and Growth of Payments
Stable Dividend: 530549 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: 530549 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 530549 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 530549's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average board tenure
CEO
Vishnukanth Bhutada (58 yo)
no data
Tenure
₹99,237,000
Compensation
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited. Mr. Bhutada joined Shilpa Medicare Limited in November 1987. He serves as the Director at Maia Phar ...
CEO Compensation Analysis
Compensation vs Market: Vishnukanth's total compensation ($USD1.34M) is above average for companies of similar size in the Indian market ($USD353.89K).
Compensation vs Earnings: Vishnukanth's compensation has increased by more than 20% in the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | no data | ₹99.24m | 11.56% ₹ 4.4b | |
| VP of Technical & Whole-time Director | 1yr | ₹5.25m | 0.034% ₹ 13.1m | |
| Independent Director | 10.58yrs | ₹40.00k | 0.11% ₹ 43.5m | |
| Additional Independent Director | 0.92yr | ₹20.00k | no data | |
| Non-Executive Chairman | no data | ₹40.00k | 3.52% ₹ 1.3b | |
| Independent Director | 12.33yrs | ₹40.00k | 0.031% ₹ 11.9m | |
| Non-Executive Director | 3.83yrs | no data | no data | |
| Independent Woman Director | 1.5yrs | ₹40.00k | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Board: 530549's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 530549 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shilpa Medicare Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shilpa Medicare Limited
- Ticker: 530549
- Exchange: BSE
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹38.155b
- Shares outstanding: 81.53m
- Website: https://www.vbshilpa.com
Location
- Shilpa Medicare Limited
- Shilpa House
- #12-6-214/A1
- Raichur
- Karnataka
- 584135
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 530549 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Jul 1995 |
| SHILPAMED | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Jul 1995 |
Biography
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (API’s), intermediates, and formulations in India, the United States, Europe, and internati ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/25 13:01 |
| End of Day Share Price | 2020/10/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.